Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
A panelist discusses how managing adverse events (AEs) in patients with chronic graft-vs-host disease (cGVHD) treated with ruxolitinib requires a structured monitoring approach that balances therapeutic efficacy with patient safety through regular clinical evaluations, laboratory assessments, and proactive management strategies tailored to individual risk profiles.
Video content above is prompted by the following:
- How do you monitor and mitigate AEs in patients with cGVHD treated with ruxolitinib?
- What are the key signs to monitor?
- How does the risk of infection change your treatment approach?
- When do you consider dose modifications or treatment discontinuation?
- What is your approach to patient education when treating steroid-refractory cGVHD?
- Please discuss how treatments impact quality of life and share strategies to keep patients informed about, eg, disease response and symptoms to look out for.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
